Larotrectinib (LOXO-101) Trials
Call us to find out more information about TRK fusion testing, larotrectinib (LOXO-101), and clinical trial access.
Clinical Trial Hotline
Loxo Oncology’s lead investigational agent for TRK inhibition,
Loxo Oncology’s lead therapy in clinical development,
Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally bound to other genes, resulting in growth signals that can lead to cancer in many sites of the body. Patients with advanced cancer who seek out tumor profiling or comprehensive cancer genetic testing may discover that their tumor harbors a TRK fusion, as this genetic event has been described across many tumor types, including:
- Acute myeloid leukemia
- Brain low-grade glioma
- Breast cancer
- Colorectal cancer
- Congenital mesoblastic nephroma
- Gastrointestinal stromal tumors
- Glioblastoma multiforme
- Head and neck squamous cell cancer
- Infantile fibrosarcoma
- Intrahepatic cholangiocarcinoma
- Lung cancer
- Mammary analog secretory carcinoma of salivary gland origin
- Secretory breast cancer
- Thyroid cancer
Larotrectinib (LOXO-101) was designed to target TRK, turning off the signaling pathway that allows TRK fusion cancers to grow. Larotrectinib (LOXO-101) was developed in partnership with Array BioPharma.
Both the FDA and EMA have granted orphan drug designation for
Global, multicenter, single-arm, open-label, Phase 2 basket trial in patients with solid tumors with a fusion of NTRK1, NTRK2, or NTRK3.
Loxo Oncology collaborates with the clinical, laboratory, and molecular pathology communities in both academia and industry to help ensure that patients with TRK fusions and their treating physicians are notified about the larotrectinib (
This Phase 1/2 clinical trial is a multicenter, open-label trial in pediatric patients with advanced solid or primary central nervous system tumors. The trial uses a liquid formulation of larotrectinib (
For additional information about any of the
Interested physicians and patients can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at
Loxo Oncology is committed to helping patients who have not responded to available therapies and may benefit from its investigational therapies. Loxo Oncology's Policy for Access to Investigational Agents describes the principles and government regulations that the company will follow when considering a request.